How Sapu Indexed 28 Million PubMed Abstracts to Accelerate Cancer Research with Qdrant

Sapu is an early-stage biopharmaceutical company developing treatments for hard-to-treat cancers. From its San Diego facility, the team is pioneering a nanomedicine pipeline that takes existing FDA-approved drugs and re-engineers them at the nanoscale, making them smaller, more effective, and less toxic. Building on already-approved compounds gives Sapu a stronger and faster path to therapeutic success in an industry where most candidates never reach patients.